Immunotherapy using PD‐L1/PD‐1 blockade can re‐activate the immune system to attack cancer cells, which has revolutionarily changed the cancer therapy.[10, 54] PD‐L1 expression is associated with the response to PD‐1 or PD‐L1 inhibitors.[11, 12] Thus, it is urgent to further reveal the underling mechanisms regulating PD‐L1 expression. Here, CD274 is linked to cancer.